

Supplementary Material

Carbonic anhydrase IX-targeted α -radionuclide therapy with ^{225}Ac inhibits tumor growth in a renal cell carcinoma model

Robin I.J. Merks^{1,2*}, Mark Rijpkema¹, Gerben M. Franssen¹, Annemarie Kip¹, Bart Smeets³, Alfred Morgenstern⁴, Frank Bruchertseifer⁴, Eddie Yan⁵, Michael P. Wheatcroft⁵, Egbert Oosterwijk², Peter F.A. Mulders², Sandra Heskamp¹

¹Department of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands ²Department of Urology, Radboudumc, Nijmegen, The Netherlands

³Department of Pathology, Radboudumc, Nijmegen, The Netherlands

⁴European Commission, Joint Research Centre (JRC), Karlsruhe, Germany

⁵Telix Pharmaceuticals Limited, Melbourne, Australia

Correspondence: Robin.Merks@radboudumc.nl;

Table S1.

The weight, the absolute uptake, and relative uptake over time of the spleen in mice treated with 50 kBq ^{225}Ac -hG250.

Mouse	Day 1				Day 3				Day 7		
	Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)		Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)		Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)
1	0.0716	0.390	5.450		0.0266	0.236	8.864		0.0138	0.189	13.687
2	0.0729	0.443	6.083		0.031	0.311	10.024		0.0178	0.315	17.679
3	0.0782	0.484	6.185		0.0475	0.305	6.415		0.0147	0.268	18.218
4	0.0699	0.414	5.928		0.0413	0.421	10.198		0.1703	0.155	0.913
5	0.0639	0.334	5.228		0.0573	0.546	9.524		0.0182	0.260	14.273

Table S2.

The weight, the absolute uptake, and relative uptake over time of the spleen in mice treated with 0.2 MBq ^{177}Lu -hG250.

Mouse	Day 1				Day 3				Day 7		
	Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)		Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)		Weight (g)	Absolute Uptake (%ID)	Relative Uptake (%ID/g)
1	0.0802	0.502	6.259		0.1198	0.453	3.784		0.1571	0.399	2.538
2	0.1038	0.513	4.947		0.1071	0.499	4.655		0.1276	0.332	2.601
3	0.0822	0.360	4.374		0.0798	0.338	4.235		0.2067	0.430	2.078
4	0.1586	0.405	2.556		0.2136	1.044	4.889		0.1112	0.310	2.789
5	0.1135	0.333	2.930		0.1091	0.408	3.744		0.1618	0.490	3.026




Figure S1. Continuous measurement of ^{213}Bi in organs of interest (blood, tumor, liver, and kidney) at three time points post-administration. All data points are based on the mean \pm SD on that time point (n=5). The curve was obtained by applying a one-phase decay fit in all groups. The Y-axis on all graphs represents %ID/g of ^{213}Bi .




Figure S2. Survival curves of SK-RC-52 tumor-bearing mice, either untreated or treated with different activity doses of ^{225}Ac -hG250 or ^{177}Lu -hG250.




Figure S3. Absolute body weight over time in non-tumor-bearing mice either untreated or treated with different doses of ^{225}Ac -hG250 or ^{177}Lu -hG250.




Figure S4. Relative body weight over time in tumor-bearing mice either untreated or treated with different doses of ^{225}Ac -hG250 or ^{177}Lu -hG250.




Figure S5. Representative kidney slices stained with periodic acid-Schiff from non-tumor-bearing mice either untreated or treated with different doses of ^{225}Ac -hG250 or ^{177}Lu -hG250, 18 weeks post-treatment. Mice treated with 15 and 25 kBq ^{225}Ac -hG250 show interstitial fibrosis and tubular atrophy in the kidney.